BTIG raised the firm’s price target on LifeStance (LFST) to $10 from $9 and keeps a Buy rating on the shares. Heading into 2026 we believe that medical utilization will remain high driven by a healthy labor market, rising specialty and oncology Rx demand, new specialty medications coming to market, more demand for mental health services, and increases in post-acute utilization – all macro factors expected to benefit LifeStance, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFST:
- LifeStance initiated with an Overweight at Barclays
- LifeStance management to meet virtually with KeyBanc
- LifeStance management to meet virtually with BTIG
- LifeStance initiated with an Outperform at BMO Capital
- Positive Outlook for LifeStance Health Group: Overcoming Challenges and Driving Growth with Strategic Initiatives